Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZYPREXA RELPREVV vs INVEGA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Olanzapine pamoate is a second-generation antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also binds to adrenergic α1, histamine H1, and muscarinic M1 receptors.
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also acts as an antagonist at α1 and α2 adrenergic receptors and H1 histaminergic receptors. It has no affinity for muscarinic receptors.
Schizophrenia (FDA approved),Maintenance treatment of schizophrenia after stabilization with oral olanzapine
Treatment of schizophrenia (FDA),Treatment of schizoaffective disorder (FDA),Monotherapy or adjunctive therapy for acute manic or mixed episodes associated with bipolar I disorder (off-label),Maintenance treatment of bipolar I disorder (off-label),Aggression in autism (off-label),Tourette syndrome (off-label)
210 mg intramuscular injection every 2 weeks; range 150-300 mg; max 300 mg per dose. For olanzapine-naive patients, establish tolerability with oral olanzapine before initiation.
Oral: 6 mg once daily; may increase to 9 mg/day if needed. IM (extended-release): 234 mg on day 1, 156 mg on day 8, then 117 mg monthly; adjust within range 39-234 mg per month.
The terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) after intramuscular injection, consistent with extended release from the depot formulation.
Terminal elimination half-life is approximately 23-29 hours for oral administration (paliperidone extended-release). Once-daily dosing achieves steady-state within 4-5 days.
Primarily metabolized by direct glucuronidation (UGT1A4) and oxidative metabolism via CYP1A2, with minor contributions from CYP2D6 and CYP3A4.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use caution.
Cr Cl >=50 m L/min: no adjustment. Cr Cl 10-49 m L/min: oral max 3 mg daily; IM initial 156 mg on day 1, 78 mg on day 8, then 39-78 mg monthly. Cr Cl <10 m L/min: not recommended.
Post-injection delirium/sedation syndrome (PDSS): Following injection, patients may experience symptoms consistent with olanzapine overdose, including sedation, coma, and delirium. Patients must be observed for at least 3 hours after each injection in a registered healthcare facility.
First trimester: Limited data, but olanzapine is associated with a small increased risk of neural tube defects and possibly other malformations based on some studies; however, the absolute risk remains low. Second and third trimesters: Exposure may lead to extrapyramidal symptoms and/or withdrawal symptoms in neonates, including agitation, hypertonia, hypotonia, tremors, somnolence, respiratory distress, and feeding difficulties. Overall, risk is considered moderate; benefits may outweigh risks in severe maternal psychiatric illness.
Paliperidone (INVEGA) is not teratogenic in animal studies at doses up to 2 times the human therapeutic dose. No adequate well-controlled studies in pregnant women. Third trimester exposure to antipsychotics may cause extrapyramidal symptoms or withdrawal in neonates. Use only if benefit outweighs risk; register patient in Atypical Antipsychotics Pregnancy Registry (1-866-961-2388).
Zyprexa Relprevv (olanzapine pamoate) is a long-acting injectable atypical antipsychotic for schizophrenia. Due to risk of post-injection delirium/sedation syndrome (PDSS), patients must be observed for 3 hours in a healthcare facility after each injection. Do not confuse with Zyprexa (oral) or Zyprexa Intramuscular (short-acting). Initiate with oral olanzapine to establish tolerability before starting injectable. Avoid in patients with known risk factors for QT prolongation or seizures.
INVEGA (paliperidone) is the major active metabolite of risperidone, offering a similar efficacy profile with potentially less need for dose adjustment in hepatic impairment. It is FDA-approved for schizophrenia and schizoaffective disorder. The extended-release oral formulation (OROS) provides once-daily dosing with a gradual release over 24 hours. Dose titration is generally not required but may be necessary based on renal function; reduce dose in moderate renal impairment (Cr Cl 30-49 m L/min) and avoid in severe impairment (Cr Cl <30 m L/min). Monitor for extrapyramidal symptoms, weight gain, metabolic changes (glucose, lipids), and prolactin elevation. QT prolongation risk is lower than with some antipsychotics but still present; caution with other QT-prolonging drugs. Taper when discontinuing to avoid withdrawal symptoms or rebound psychosis.
No interactions on record
No interactions on record
ZYPREXA RELPREVV and INVEGA are distinct pharmacological agents. ZYPREXA RELPREVV belongs to the Atypical Antipsychotic class and is primarily used for Schizophrenia (FDA approved)Maintenance treatment of schizophrenia after stabilization with oral olanzapine. INVEGA belongs to the Atypical Antipsychotic class and is primarily used for Treatment of schizophrenia (FDA)Treatment of schizoaffective disorder (FDA)Monotherapy or adjunctive therapy for acute manic or mixed episodes associated with bipolar I disorder (off-label)Maintenance treatment of bipolar I disorder (off-label)Aggression in autism (off-label)Tourette syndrome (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. ZYPREXA RELPREVV carries a safety status of Category C, whereas INVEGA safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Paliperidone is primarily metabolized via N-dealkylation and monohydroxylation, with minor contributions from CYP2D6 and CYP3A4. It is a substrate for P-glycoprotein (P-gp). Approximately 59% of the dose is excreted unchanged in urine, indicating that renal excretion is a major route of elimination.
Approximately 57% of the dose is excreted in urine (30% as unchanged drug, 27% as metabolites) and 30% in feces (primarily as metabolites).
Primarily renal: 59-80% of dose excreted unchanged in urine (as parent drug and metabolites). Fecal: ~20-30%. Biliary elimination is minimal.
Approximately 93% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
Paliperidone is 74% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 1000–1500 L (14–22 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Volume of distribution is 0.7 L/kg (range 0.5-1.0 L/kg), indicating moderate tissue distribution.
Bioavailability is 100% for the intramuscular route as it is a parenteral depot formulation; oral olanzapine bioavailability is 60% (not applicable for this formulation).
Oral (extended-release): Absolute bioavailability is 28% due to first-pass metabolism. The extended-release formulation provides a smooth plasma concentration profile.
Child-Pugh Class A or B: no adjustment recommended. Child-Pugh Class C: use caution; lower starting dose may be considered due to potential increased exposure.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): not studied.
Safety and efficacy not established in pediatric patients; not recommended for use under 18 years of age.
Adolescents (12-17 years, weight >=51 kg): oral 3 mg once daily; can increase to 6 mg/day after 5 days, then max 12 mg/day. For IM, safety in adolescents not established.
Initial dose of 150 mg intramuscularly every 4 weeks; may consider slower titration. Monitor for orthostatic hypotension, sedation, and extrapyramidal symptoms. Not recommended for elderly patients with dementia-related psychosis due to increased mortality risk.
Initiate oral at 3 mg once daily; may increase to 6 mg/day after 5 days. For IM, start with 156 mg on day 1, 78 mg on day 8, then 39-78 mg monthly. Use lowest effective dose due to increased sensitivity.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA is not approved for the treatment of patients with dementia-related psychosis.
No specific food interactions. However, alcohol may increase sedation and CNS depression; advise avoidance. Grapefruit juice has no known significant interaction but monitor for weight gain and metabolic changes; encourage a healthy diet.
Avoid concomitant consumption of grapefruit or grapefruit juice, as grapefruit inhibits CYP3A4 and may increase paliperidone concentrations. Alcohol should be avoided due to additive CNS depression. High-fat meals may increase absorption of the oral tablet; take consistently with or without food, but avoid high-fat meals during the first few days of treatment to reduce variability.
Olanzapine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.2–0.84. The estimated infant dose via breast milk is about 1-2% of the maternal weight-adjusted dose. Limited data suggest no consistent adverse effects in breastfed infants, but monitoring for sedation, irritability, and poor feeding is recommended. Breastfeeding is generally acceptable with careful infant monitoring.
Paliperidone is excreted in human breast milk. The milk-to-plasma ratio is unknown. In a study of 7 women, paliperidone was detected in milk (range 4.0-8.9 ng/m L), with relative infant dose estimated at <5% of maternal weight-adjusted dose. Caution: monitor infant for sedation, poor feeding, and extrapyramidal signs.
Pregnancy can decrease olanzapine plasma concentrations by 30-50% during the second and third trimesters due to increased volume of distribution and enhanced hepatic clearance. Dose increases may be necessary to maintain therapeutic efficacy, with careful monitoring for safety. Postpartum, doses should be reduced to pre-pregnancy levels within 48-72 hours to avoid toxicity. Therapeutic drug monitoring is recommended if available.
Pregnancy may reduce paliperidone exposure due to increased volume of distribution and hepatic clearance. Limited data: in a case report, dose increase of 50% was needed in third trimester to maintain efficacy. Monitor therapeutic response and adjust dose as needed, with close monitoring for relapse. Postpartum: consider gradual dose reduction to pre-pregnancy levels.
You must stay at the doctor's office or clinic for 3 hours after each injection to monitor for serious side effects.,After leaving, avoid driving or operating heavy machinery for the rest of the day after your injection.,This medication is given every 2 to 4 weeks; do not miss appointments.,Call your doctor immediately if you experience excessive sleepiness, dizziness, confusion, or trouble breathing after the injection.,Report any unusual muscle movements, fever, sweating, or fast heartbeat.
Take this medication once daily at the same time each day; do not crush, chew, or dissolve the tablet, as it uses a special delivery system.,You may see a tablet shell in your stool; this is normal and does not mean the medication wasn't absorbed.,Avoid alcohol and grapefruit/grapefruit juice while taking INVEGA as they can affect how it works.,Seek medical help if you experience symptoms of neuroleptic malignant syndrome (fever, muscle rigidity, confusion) or tardive dyskinesia (involuntary movements).,Do not stop taking INVEGA abruptly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms.,Report signs of high blood sugar (increased thirst, hunger, urination), unusual weight gain, or changes in menstrual periods or breast enlargement/discharge.,INVEGA may cause dizziness, drowsiness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,If you are pregnant or planning to become pregnant, discuss the risks and benefits with your doctor; a pregnancy registry is available.